Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy – Lymphoma News Today
|
Incysus Seeks FDA Approval to Start Blood Cancer Trials for Its γδ T-Cell Immunotherapy
Lymphoma News Today Incysus has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to start clinical development of its expanded and activated allogeneic gamma-delta (γδ) T-cell therapy for patients with blood cancers who … |
